Akeso and Summit Therapeutics’ giant-killing, PD-1xVEGF bispecific antibody ivonescimab has posted another phase 3 trial win ...

Approval of penpulimab-kcqx marks the company’s US regulatory debut and introduces a new immunotherapy option for advanced ...

In patients with advanced squamous non–small cell lung cancer, ivonescimab plus chemo was associated with progression-free ...

DelveInsight's "Metastatic Cutaneous Squamous Cell Cancer Market Insights, Epidemiology, and Market Forecast- 2032" report ...

A study suggests that antibiotic use within one month of immune checkpoint inhibitor treatment may undermine survival in ...

Master Regulator Blocking Immunotherapy, Paving the Way for a New Lung Cancer Treatment Apr. 9 ... that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific ...

BioNTech stock rocketed Wednesday after rival Summit Therapeutics unveiled promising results for a novel approach to lung cancer treatment.Summit's Akeso-partnered drug, ivonescimab, works by blocking ...

Ivonescimab plus chemotherapy improved survival in advanced squamous NSCLC vs tislelizumab and chemotherapy in a phase 3 ...

Summit Therapeutics shares rallied after its lung cancer drug candidate showed that it improved patients' longevity without the disease worsening in a late-stage trial. Shares of Summit rose 11% to ...

Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of ...

“The CE Mark approval for Optune Lua for metastatic non-small cell lung cancer is a significant ... Mark approval for the treatment of patients with stage IV, non-squamous NSCLC in combination ...